Fig. 5

PDGF-BB enhances the crosstalk of fibroblasts and epidermal cells. a Western blot analysis and the relative level of phosphorylated FGFR-2 and Erk1/2 in L929 cells after treating with the combining 5% control plasma (Control), 5% bone defect plasma (Bone defect) and 5% bone defect plasma combining1uM Sunitinib (Bone defect + Sunitinib) for 20 min (n = 3). b Quantitative statistics of the percentage of Edu⁺ L929 cells treated with indicated plasma by flow cytometry for 48 h (n = 4). c The average migration distance of L929 cells in different groups was quantitatively analyzed according to scratch test (n = 8). Scale bar, 200 μm. d KGF protein expressions of L929 cell conditional medium by Elisa (n = 4). e Western blot analysis and the relative level of phosphorylated FGFR-2 and Erk1/2 in HaCaT after treating with the indicated L929 CM for 20 min (n = 3). f Quantitative statistics of the percentage of Edu⁺ HaCaT cells by flow cytometry. Cells were treated with L929-Control-CM, L929-BD-CM, and L929-BD+Sunitinib-CM, respectively for 48 h (n = 4). g The average migration distance of HaCaT cells treated with differenced CM was quantitatively analyzed according to scratch test. Yellow dashed line marks scratch wound edges (n = 8). Scale bar, 200 μm. h Heatmap showing the relative mRNA expression of HaCaT cells by qPCR (n = 3). The values were the multiple of the gene expression of each gene relative to that of 10% FBS treated HaCaT cells. i Illustration of the mechanism of skin wound healing induced by bone defect. Data are presented as mean ± SD and statistical significance was analyzed via one-way ANOVA with Tukey’s multiple comparison test for (a, b, d, e, f), two-way ANOVA with Tukey’s multiple comparison test for (c, g). P value: *P < 0.05, **P < 0.01, ***P < 0.001